Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa ( hFXIa , with a K a of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1 , selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases.
Products | Products > Peptides | Products > Disease Areas > Disc Degeneration | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Spinal Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Factor Xa | Products > Signaling Pathways > TGF-beta/Smad
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.